Inhibitors of the fibroblast growth factor receptor
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
1. A compound of Formula II or a pharmaceutically acceptable salt thereof:
wherein:
ring A is a tetrahydrofuranyl or tetrahydropyranyl;
R 1 is halo, cyano, C 1-6 alkoxy, hydroxy, oxo, amino, amido, or C 1-6 alkyl;
each R 2 is, independently, halo or C 1-6 alkoxy;
R 3 is halo; and
m is 0-1;
n is 1-4; and
p is 0.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein ring A is tetrahydrofuranyl.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein ring A is tetrahydropyranyl.
4. A compound selected from the compounds below or a pharmaceutically acceptable salt thereof:
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the portion of the compound represented by
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 4.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein m is 0.
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein ring A is tetrahydropyranyl and m is 0.
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.
10. A method of treating a hepatocellular carcinoma mediated by FGFR-4, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.